Australian eyecare professionals wanting to elevate their dry eye management and treat inflammation can access the latest intense pulse light (IPL) from Lumenis. OptiLight is the only light-based technology that is FDA approved and TGA listed for the treatment of DED and MGD.
The company, which pioneered intense pulsed light (IPL) technology, secured US Food and Drug Administration (FDA) De Novo authorisation for OptiLight in 2021. It is Lumenis’ newest IPL device for the treatment of dry eye disease (DED) due to meibomian gland dysfunction (MGD), which is also available in Australia.
The world’s largest energy-based medical device company for ophthalmic and aesthetic applications said the multi-centre, double-blinded, randomised controlled FDA trial showed Lumenis IPL with patented Optimal Pulse Technology (OPT) significantly improved tear breakup time, meibum quality, and meibomian gland expressibility.1
The clinical trial joins other studies of Lumenis’ IPL with OPT, that have shown the same results, as well as reduction of inflammatory markers.2-5
Subsequent to the FDA approval and Australian Therapeutic Goods Administration (TGA) listing, Lumenis launched OptiLight which is designed for a consistent, precise, and controlled light-based treatment for dry eye disease.
“In my clinic we deal with dry eye disease every day and have found that in order to make a meaningful impact on the disease, we need to address the underlying inflammation,” Dr Jason Holland, lead clinical optometrist at The Eye Health Centre in Queensland, said.
“Lumenis’ OPT technology helps us to address inflammation, as shown in published clinical trials, which improves the signs and symptoms of dry eye disease due to MGD. Lumenis’ OPT is an essential tool in our dry eye toolkit.”
Lumenis ANZ country manager Mr Paul Vujevic said the company had launched many “firsts” in eyecare.
“And we never stop innovating – which is why we are proud our new patented OPT technology, OptiLight -which is the first and only such device to receive FDA approval for the treatment of dry eye disease,” he said.
“As a business we are committed to elevating dry eye management to further improve the quality of life for millions of Australian patients.”
Lumenis unveiled the OptiLight for the Australian and New Zealand market in November 2021.
Dry eye disease is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision. In January 2020, Optometry Australia reported around 77%6 of Australians have suffered from dry eye symptoms, yet only 26%6 have visited an optometrist to discuss treatment options. Current literature even suggests that up to 86%7 of dry eye patients demonstrate signs of MGD.
References
- FDA study sponsored by Lumenis: internal reference LUM-VBU-M22-IPL-17-01.
- Yan et al. (2020), Eye & Contact Lens 2021, 27(1):45-53.
- Arita et al. (2019) Ocul Surf 17(1):308-13.
- Gao et al. (2019) Int J Ophthalmol 12(11):1708-1713.
- Liu et al. (2017) Am J Ophthalmol 183:81-90.
- Optometry Australia, the 2020 Vision Index Report
- Lemp et al. 2012
More reading
How dry eye can elevate your practice
Dry eye – a multifactorial approach to a multifactorial disease
